The global peptide drug conjugates market size was valued at USD 596.27 million in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 18.58% from 2022 to 2030. The robust clinical trial pipeline with peptide drug conjugates (PDCs) coupled with increase in R&D investments for developing PDCs and rising disease burden across the globe are the factors expected to contribute to the market growth. For instance, in July 2021, Takeda Pharmaceutical Company Limited in collaboration with Peptide Dream, announced to invest USD 3.5 billion to develop peptide drugs for neuromuscular disease.
Pharmaceutical companies are developing PDCs as targeted therapeutic drugs for the metabolic diseases, Covid-19 viral diseases, and cancer among others. Currently, the market has presence of two FDA approved drugs Pepaxto (Melflufen) and Lutathera (Lu 177 dotatate) for cancer treatment. Therefore, rising prevalence of such diseases is driving the peptide drug conjugates market. According to National Cancer Institute, in 2020, more than 1.8 million new cancer cases and more than 600,000 deaths occurred in the U.S. due to the cancer.
The strong product pipeline and increasing financial investments in research and development is offering lucrative opportunity for the peptide drug conjugates market growth. For instance, Angio Chem, Inc.’s product candidate- ANG1005 indicated for brain tumor is undergoing phase 3 clinical studies, Bicycle Therapeutics pipeline products- BT5528&BT1718 indicated for non-small cell carcinoma, are under phase 2 clinical trials. Hence, the expected new PDC approval for treatment of multiple types of cancer will boost the market growth in near future.
According to the national cancer institute, there are more than 250 FDA approved chemotherapeutic drugs used in the treatment of malignant tumors. However, the major drawback associated with such small molecules is uncontrolled toxicity resulting into severe side effects. Moreover, increasing drug resistance of tumor cells to such agents has led to demand for the better treatment approach like targeted PDCs and thereby, driving the peptide drug conjugates space. However, low bioactivity, poor stability, long research and development time, and slow clinical development process as therapeutic agents of PDC is expected to restrain the segment, leading to increase in overall time and cost incurred for the development.
The Lutathera product segment dominated thepeptide drug conjugates market with a revenue share of 80.5% in 2021. The first FDA approved PDC is Novartis’s Lutathera (lutetium Lu 177), a radio labeled somatostatin analog which is an advanced accelerator injection. The expected patent expiry date is 25th July 2038. Itis indicated for the treatment of somatostatin receptor-positive gastro enteropancreatic neuroendocrine tumors including foregut, midgut, and hindgut neuroendocrine tumors in adults. Lutathera consist of an amide linkage between homing peptide somatostatin and cytotoxic radiotherapeutic agent 177Lu.
Oncopeptides ABreceived FDA approval for its first-in-classpeptide-conjugated alkylator, Pepaxto (melflufen), in February 2021. The combination of Pepaxto (Melphalan flufenamide) with dexamethasone is indicated for the multiple myeloma in adult patients. The drug has demonstrated anti-myeloma activity in myeloma tumor cells resistant to bortezomib and the alkylator melphalan. Melflufen patents cover major markets in the US, Japan, Canada, and Europe. However, the drug has been withdrawn from the U.S. market in October 2021, based on overall survival data from its phase 3 study.
Therapeutic segment dominated the peptide drug conjugatesmarket with the revenue share of 82.3% in 2021 and is anticipated to witness the fastest growth. The factors attributing to dominance is the presence of both approved PDCs, Lutathera and Pepaxtoas therapeutic agents targeting tumor cells. Moreover, the presence of targeting therapeutic drugs such as ANG1005,
BT5528 and BT1718 under clinical trials are expected to boost the market during the forecast period. Along with cancer, pharmaceutical companies are developing targeting therapeutic PDCs for metabolic diseases and coronavirus diseases due to the significant benefits of PDCs in therapeutic segment.
PDCs coupled with radionucleotides, can also act as diagnostic agents. For example,Mallinckrodt Pharmaceuticals’ In-DTPA-octreotide (octreoscan) which contains radioactive nucleotide, primarily used in localization of neuroendocrine tumors. Furthermore, development and applications of PDCs in diagnosis is anticipated to offer remunerative opportunity for the segment growth.
North America dominated the overall peptide drug conjugates (PDCs) market in terms of revenue share of 45.62% in 2021, owing to the launch of Melflufen and rapid uptake of PDC drugs in cancer therapy. Increasing awareness about current treatment options, favorable reimbursement policies, and improved patient affordability are the factors expected to drive the market growth. Furthermore, rising cases of cancer and related mortality is fueling the market growth in the region. For instance, NCI reported approximately 1,806,590 new cancer cases and 606,520 disease related deaths in 2020.
Asia Pacific is expected to witness a growth rate of 27.4% during the forecast period. Growth of the region is attributed to the upsurge in number of cancer cases and strategic initiatives undertaken by the market players for regional expansion in such regions. Furthermore, rising research and development along with increasing investments to develop and commercialize such novel delivery systems is anticipated to boost the market growth in the region.
Strategic collaborations are one of the key initiatives undertaken by the companies to gain market share. In November 2022, Cybrexa Therapeutics and Exelixis, Inc. announced the collaboration agreement providing Exelixis the right to acquire, first-in-class peptide-drug conjugate (PDC), CBX-12. This initiative is expected to expand its clinical pipeline for the targeted drug therapy.
Additionally, in June 2019, Novartis AG and PeptiDream Inc. collaborated to develop PDC, macrocyclic peptide for diagnostic and therapeutic applications. Such strategic initiatives by the key players are driving the market growth.Some of the prominent players in global peptide drug conjugates market include:
Novartis AG
Oncopeptides AB
Bicycle Therapeutics
AstraZeneca
Cybrexa Therapeutics
Angiochem Inc.
Innovasium Soricimed Biopharma
Theratechnologies
Report Attribute |
Details |
Market size value in 2022 |
USD 683.97 million |
Revenue forecast in 2030 |
USD 2.67 billion |
Growth rate |
CAGR of 18.58% from 2022 to 2030 |
Base year for estimation |
2021 |
Historical data |
2018 - 2020 |
Forecast period |
2022 - 2030 |
Quantitative units |
Revenue in USD million, CAGR from 2022 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, trends |
Segments covered |
Product, type, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; U.K.; Germany; France; Spain; Italy; Japan; China; India; Australia; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE |
Key companies profiled |
Novartis AG; Bicycle Therapeutics; AstraZeneca; Cybrexa Therapeutics; Oncopeptides AB; Angiochem Inc.; Innovasium Soricimed Biopharma; Theratechnologies |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at the global, regional, & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global peptide drug conjugates market report based on the product, type, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Lutetium
Melflufen
ANG1005
BT1718
CBX-12
Other Pipeline Products
Type Outlook (Revenue, USD Million, 2018 - 2030)
Therapeutic
Diagnostic
Regional Outlook (Revenue, USD Million; 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
b. The global peptide drug conjugates market is expected to witness a compound annual growth rate of 18.58% from 2022 to 2030 to reach USD 2.67 billion by 2030.
b. Based on product, Lutathera segment accounted for a share of 80.5% in 2021 as it is the first approved PDC and solves an unmet need in neuroendocrine tumors.
b. Some of the key players in the peptide drug conjugates market are Novartis AG, Bicycle Therapeutics, AstraZeneca, Cybrexa Therapeutics, Oncopeptides AB, Angiochem Inc., Innovasium Soricimed Biopharma, and Theratechnologies.
b. The major factors driving the market growth are the global upsurge in cancer cases and related mortality, robust clinical pipeline of PDCs, and uncontrolled toxicity associated with available small molecule chemotherapeutic agents.
b. The global peptide drug conjugates market size was valued at USD 596.27 million in 2021 and is anticipated to reach USD 683.97 million in 2022.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
We value your investment and offer free customization with every report to fulfil your exact research needs.